In highly lethal type of leukemia, cancer gene predicts treatment response

Patients whose cancer cells carry TP53 mutations respond to milder chemotherapy

Patients with the most lethal form of acute myeloid leukemia (AML) – based on genetic profiles of their cancers – typically survive for only four to six months after diagnosis, order even with aggressive chemotherapy. But new research indicates that such patients, salve paradoxically, viagra 100mg may live longer if they receive a milder chemotherapy drug.

Treatment with the less intensive drug, decitabine, is not a cure. But surprisingly, AML patients whose leukemia cells carried mutations in a nefarious cancer gene called TP53 consistently achieved remission after treatment with decitabine. Their median survival was just over a year.

Read Full Article Here >>